Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $22,360.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00. Following the completion of the sale, the president now owns 2,897,138 shares of the company’s stock, valued at $32,390,002.84. The trade was a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total value of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total transaction of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total transaction of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total transaction of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total value of $25,000.00.

Gyre Therapeutics Trading Up 0.1 %

Shares of GYRE stock opened at $11.51 on Friday. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $26.37. The stock has a 50 day moving average of $11.09 and a two-hundred day moving average of $12.54.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors have recently bought and sold shares of the business. FMR LLC acquired a new position in shares of Gyre Therapeutics in the 3rd quarter valued at $47,000. Barclays PLC raised its position in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. Rhumbline Advisers acquired a new position in Gyre Therapeutics in the second quarter worth about $123,000. Renaissance Technologies LLC bought a new position in Gyre Therapeutics during the second quarter worth about $166,000. Finally, Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics during the third quarter valued at approximately $334,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.